Compare Diageo plc (DEO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Sana Biotechnology Inc — how do they compare? Diageo plc trades at $82.52 (market cap $45.41B), while Sana Biotechnology Inc trades at $3.48 (market cap $994.89M). The key difference: Diageo plc is far larger — about 45.6× Sana Biotechnology Inc's market cap, and Diageo plc pays a 4.02% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| DEO | SANA | |
|---|---|---|
Market Cap | $45.41B | $994.89M |
Sector | Technology | Health |
52-Week High | $115.33 | $5.92 |
52-Week Low | $72.47 | $2.68 |
Enterprise Value | $66.23B | $969.08M |
Dividend Yield | 4.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $82.50, up 0.57% today, with a bullish technical trend and strong profitability metrics including a 12.19% net margin and 22.29% ROE. Recent earnings show mixed results with a Q4 2025 beat but a Q2 2025 miss, while analyst sentiment is positive with 49% buy ratings. The stock faces headwinds from weak U.S. spirits demand and promotional pressures, as noted in recent Deutsche Bank and UBS reports from July 2026.
The outlook hinges on management's strategy reset in August 2026 to address U.S. volume declines and margin pressures. Investment appeal lies in its discounted valuation relative to historical multiples and dividend yield, but risks include sustained consumer moderation trends and execution challenges in key markets.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.
The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
